These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 22101352)

  • 61. Clear cell carcinoma of the ovary: Clinicopathologic features and outcomes in a Chinese cohort.
    Tang H; Liu Y; Wang X; Guan L; Chen W; Jiang H; Lu Y
    Medicine (Baltimore); 2018 May; 97(21):e10881. PubMed ID: 29794794
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Expression of ARID1A in ovarian seromucinous neoplasms and its clinicopathological significance].
    Ding XH; Tian X; Wang LQ; Wang Y; Liu AJ
    Zhonghua Bing Li Xue Za Zhi; 2020 Jun; 49(6):588-593. PubMed ID: 32486536
    [No Abstract]   [Full Text] [Related]  

  • 63. Suppression of ARID1A associated with decreased CD8 T cells improves cell survival of ovarian clear cell carcinoma.
    Jung US; Min KW; Kim DH; Kwon MJ; Park H; Jang HS
    J Gynecol Oncol; 2021 Jan; 32(1):e3. PubMed ID: 33185044
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Genome-wide DNA methylation in relation to ARID1A deficiency in ovarian clear cell carcinoma.
    Li S; Meersma GJ; Kupryjanczyk J; de Jong S; Wisman GBA
    J Transl Med; 2024 Jun; 22(1):556. PubMed ID: 38858765
    [TBL] [Abstract][Full Text] [Related]  

  • 65. ARID1A expression in early stage colorectal adenocarcinoma: an exploration of its prognostic significance.
    Lee LH; Sadot E; Ivelja S; Vakiani E; Hechtman JF; Sevinsky CJ; Klimstra DS; Ginty F; Shia J
    Hum Pathol; 2016 Jul; 53():97-104. PubMed ID: 26980037
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Clear cell carcinomas of the ovary: a multi-institutional study of 129 cases in Korea with prognostic significance of Emi1 and Galectin-3.
    Min KW; Park MH; Hong SR; Lee H; Kwon SY; Hong SH; Joo HJ; Park IA; An HJ; Suh KS; Oh HK; Yoo CW; Kim MJ; Chang HK; Jun SY; Yoon HK; Chang ED; Kim DW; Kim I;
    Int J Gynecol Pathol; 2013 Jan; 32(1):3-14. PubMed ID: 23202783
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Three versus six cycles of adjuvant platinum-based chemotherapy in early stage clear cell ovarian carcinoma - A multi-institutional cohort.
    Prendergast EN; Holzapfel M; Mueller JJ; Leitao MM; Gunderson CC; Moore KN; Erickson BK; Leath CA; Diaz Moore ES; Cohen JG; Walsh CS
    Gynecol Oncol; 2017 Feb; 144(2):274-278. PubMed ID: 27979319
    [TBL] [Abstract][Full Text] [Related]  

  • 68. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.
    Alsop K; Fereday S; Meldrum C; deFazio A; Emmanuel C; George J; Dobrovic A; Birrer MJ; Webb PM; Stewart C; Friedlander M; Fox S; Bowtell D; Mitchell G
    J Clin Oncol; 2012 Jul; 30(21):2654-63. PubMed ID: 22711857
    [TBL] [Abstract][Full Text] [Related]  

  • 69. A DNA repair pathway-focused score for prediction of outcomes in ovarian cancer treated with platinum-based chemotherapy.
    Kang J; D'Andrea AD; Kozono D
    J Natl Cancer Inst; 2012 May; 104(9):670-81. PubMed ID: 22505474
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease.
    Goff BA; Sainz de la Cuesta R; Muntz HG; Fleischhacker D; Ek M; Rice LW; Nikrui N; Tamimi HK; Cain JM; Greer BE; Fuller AF
    Gynecol Oncol; 1996 Mar; 60(3):412-7. PubMed ID: 8774649
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients.
    Mignogna C; Staropoli N; Botta C; De Marco C; Rizzuto A; Morelli M; Di Cello A; Franco R; Camastra C; Presta I; Malara N; Salvino A; Tassone P; Tagliaferri P; Barni T; Donato G; Di Vito A
    J Ovarian Res; 2016 May; 9(1):31. PubMed ID: 27209210
    [TBL] [Abstract][Full Text] [Related]  

  • 72. GLS1 is a protective factor in patients with ovarian clear cell carcinoma and its expression does not correlate with ARID1A-mutated tumors.
    Clemente V; Hoshino A; Shetty M; Nelson A; Erickson BK; Baker R; Rubin N; Khalifa M; Weroha SJ; Lou E; Bazzaro M
    Cancer Res Commun; 2022 Aug; 2(8):784-794. PubMed ID: 36082022
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Evaluation of SWI/SNF Protein Expression by Immunohistochemistry in Ovarian Clear Cell Carcinoma.
    Bennett JA; Safdar N; Segal JP; Lastra RR; Oliva E
    Int J Gynecol Pathol; 2021 Mar; 40(2):156-164. PubMed ID: 32897960
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Establishment and characterization of a novel ovarian clear cell carcinoma cell line, TU-OC-2, with loss of ARID1A expression.
    Sato S; Itamochi H; Oumi N; Chiba Y; Oishi T; Shimada M; Sato S; Chikumi J; Nonaka M; Kudoh A; Komatsu H; Harada T; Sugiyama T
    Hum Cell; 2016 Oct; 29(4):181-7. PubMed ID: 26960408
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Endometriosis does not confer improved prognosis in ovarian clear cell carcinoma: a retrospective study at a single institute.
    Zhao T; Shao Y; Liu Y; Wang X; Guan L; Lu Y
    J Ovarian Res; 2018 Jun; 11(1):53. PubMed ID: 29941051
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Anterior gradient protein 2 (AGR2) is an independent prognostic factor in ovarian high-grade serous carcinoma.
    Darb-Esfahani S; Fritzsche F; Kristiansen G; Weichert W; Sehouli J; Braicu I; Dietel M; Denkert C
    Virchows Arch; 2012 Aug; 461(2):109-16. PubMed ID: 22752467
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG oncology/gynecologic oncology group study 0283.
    O'Cearbhaill RE; Miller A; Soslow RA; Lankes HA; DeLair D; Segura S; Chavan S; Zamarin D; DeBernardo R; Moore K; Moroney J; Shahin M; Thaker PH; Wahner-Hendrickson AE; Aghajanian C
    Gynecol Oncol; 2023 Sep; 176():16-24. PubMed ID: 37418832
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The prognostic significance of the immunohistochemical expression of p53, bcl-2, c-erb B-2 and cathepsin-D in ovarian cancer patients receiving platinum with cyclophosphamide or paclitaxel chemotherapy.
    Protopapas A; Diakomanolis E; Bamias A; Milingos S; Markaki S; Papadimitriou C; Dimopoulos AM; Michalas S
    Eur J Gynaecol Oncol; 2004; 25(2):225-9. PubMed ID: 15032288
    [TBL] [Abstract][Full Text] [Related]  

  • 79. SLFN11 is a BRCA Independent Biomarker for the Response to Platinum-Based Chemotherapy in High-Grade Serous Ovarian Cancer and Clear Cell Ovarian Carcinoma.
    Akashi H; Yachida N; Ueda H; Yamaguchi M; Yamawaki K; Tamura R; Suda K; Ishiguro T; Adachi S; Nagase Y; Ueda Y; Ueda M; Abiko K; Kagabu M; Baba T; Nakaoka H; Enomoto T; Murai J; Yoshihara K
    Mol Cancer Ther; 2024 Jan; 23(1):106-116. PubMed ID: 37717249
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Endometriosis does not confer improved prognosis in ovarian carcinoma of uniform cell type.
    Cuff J; Longacre TA
    Am J Surg Pathol; 2012 May; 36(5):688-95. PubMed ID: 22498820
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.